Skip to main content
. Author manuscript; available in PMC: 2011 Apr 30.
Published in final edited form as: J Cardiovasc Pharmacol. 2010 Jan;55(1):14–20. doi: 10.1097/FJC.0b013e3181c5e743

Table 3.

End-Systolic and End-Diastolic Pressure-Volume Relationship and Analysis

Sham (n=7) HF (n=5) BNP (n=7)
In-Vivo ESPVR
 Ees (mmHg/ml) 9.53 ± 1.26 8.12 ± 3.14 21.09 ± 11.01
 V0 (ml) 3.00 ± 2.30 −50.06 ± 56.34* 4.77 ± 4.26
 SW (mmHg*RVU) 498 ± 108 295 ± 235 379 ± 144
 PAMP (mWatts/RVU2) 56.0 ± 9.8 52.4 ± 24.1 52.1 ± 12.2
 Ea (mmHg/RVU) 28.1 ± 5.9 32.9 ± 9.8 33.3 ± 8.3
Ex-Vivo EDPVR
 α (unitless) 37.3 ± 4.70 25.5 ± 2.0 27.5 ± 4.0
 β (mmHg) 0 0 0
 V30 (ml) 0.51 ± 0.04 0.85 ± 0.11* 0.77 ± 0.07
*

p<0.05 vs Sham, ** p<0.01 vs Sham

ESPVR-End-Systolic Pressure-Volume Relationship, EDPVR-End-Diastolic Pressure-Volume Relationship, HF-Heart Failure, Ees-End-systolic Elastance, V0-Volume Intercept, SW-Stroke Work, PAMP-Preload-Adjusted Maximum Power, Ea-Arterial Elastance, Ea-Arterial Elastance, RVU-Relative Volume Unit, α-Myocardial Stiffness, β-Stiffness Constant, V30-Volume at Pressure 30 mmHg